NMD Pharma

NMD Pharma is a private, clinical-stage biotechnology company pioneering a novel approach to treating neuromuscular diseases by targeting skeletal muscle-specific ClC-1 ion channels. Founded in 2015 and headquartered in Aarhus, Denmark, the company has built a proprietary muscle electrophysiology platform to develop small molecule therapies aimed at improving muscle strength and reducing fatigue. With a lead candidate, ignaseclant, in Phase 2 trials for multiple indications and approximately $180 million raised from investors, NMD is advancing a pipeline targeting rare neuromuscular and broader age-related conditions with significant unmet need.

Proprietary muscle electrophysiology and translational research platform integrating deep biological insight into ion channel function, proprietary technologies, small-molecule drug discovery, and in vivo models to develop ClC-1 inhibitors.

Competition includes companies developing novel gene therapies, antibodies, and other small molecules for neuromuscular diseases (e.g., for SMA, gMG). NMD's unique differentiation is its direct targeting of skeletal muscle excitability via ClC-1, a symptomatic approach that could be complementary to disease-modifying therapies.